(Reuters) - Amylin Pharmaceuticals Inc (AMLN.O) reported a narrower net loss for the fourth quarter as lower costs -- including the elimination of employee bonuses -- helped offset weaker sales of Byetta, a diabetes drug it sells with Eli Lilly and Co (LLY.N).
